527 related articles for article (PubMed ID: 24219333)
21. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
22. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
23. Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Lisman T; Kamphuisen PW; Northup PG; Porte RJ
J Hepatol; 2013 Aug; 59(2):358-66. PubMed ID: 23548197
[TBL] [Abstract][Full Text] [Related]
24. Novel direct factor IIa and Xa inhibitors: mechanisms of action and preclinical studies.
Deftereos S; Anatoliotakis N; Giannopoulos G; Kaoukis A; Mavri M; Pyrgakis V; Stefanadis C
Curr Clin Pharmacol; 2012 Aug; 7(3):149-65. PubMed ID: 22564123
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC; White A; Luettgen J
Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
[TBL] [Abstract][Full Text] [Related]
27. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
[TBL] [Abstract][Full Text] [Related]
28. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
Firriolo FJ; Hupp WS
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):431-41. PubMed ID: 22668425
[TBL] [Abstract][Full Text] [Related]
29. Laboratory monitoring of the non-vitamin K oral anticoagulants.
Blann AD; Lip GY
J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
[No Abstract] [Full Text] [Related]
30. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
[TBL] [Abstract][Full Text] [Related]
31. [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P
Ann Fr Anesth Reanim; 2013 Oct; 32(10):691-700. PubMed ID: 23993157
[TBL] [Abstract][Full Text] [Related]
32. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
33. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin.
Lehman CM; Rettmann JA; Wilson LW; Markewitz BA
Am J Clin Pathol; 2006 Sep; 126(3):416-21. PubMed ID: 16880140
[TBL] [Abstract][Full Text] [Related]
34. Acute management of bleeding in patients on novel oral anticoagulants.
Siegal DM; Crowther MA
Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
[TBL] [Abstract][Full Text] [Related]
35. [From old to new anticoagulants: the role of the biologist].
Samama M; Depasse F
Ann Biol Clin (Paris); 2009; 67(5):525-34. PubMed ID: 19789124
[TBL] [Abstract][Full Text] [Related]
36. [Assessment of anti-factor Xa activity for heparin and related products by chromogenic assays and thrombin generation tests].
Suzuki A; Kaneko M; Kanno N; Yatomi Y
Rinsho Byori; 2013 Jul; 61(7):567-75. PubMed ID: 24205696
[TBL] [Abstract][Full Text] [Related]
37. Anticoagulation without monitoring.
Chandler WL
Am J Clin Pathol; 2013 Nov; 140(5):606-7. PubMed ID: 24124137
[No Abstract] [Full Text] [Related]
38. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
Schellong S
Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
[TBL] [Abstract][Full Text] [Related]
39. Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
Baruch L
Postgrad Med; 2013 Mar; 125(2):135-45. PubMed ID: 23816779
[TBL] [Abstract][Full Text] [Related]
40. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
